Drugs / SSKI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04743661 Background | Apr 2022 → Mar 2026 overdue | ependymoma, medulloblastoma | Pediatric Brain Tumor Consortium | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSKI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04743661 ↗ |
| Route | Oral | “SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily” NCT04743661 ↗ |
| Route | Other | “SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily” NCT04743661 ↗ |